Case Report: Multiple TIL Therapy for Aggressive Mucosal Melanoma

A figshare-hosted clinical case report authored by Fenge Li, last updated in April 2026. The 13.9 KB document details a patient with stage IV nasal mucosal melanoma who received multiple cycles of autologous tumor-infiltrating lymphocyte therapy combined with immune checkpoint inhibitors. The report describes treatment protocols, clinical responses, adverse events, and longitudinal immune monitoring.

Use Cases

• Analyze longitudinal immune response patterns based on peripheral blood cell subtyping and cytokine secretion data mentioned in the description.
• Study the safety profile and adverse event management of multiple TIL infusions as described in the case report.
• Review the feasibility and clinical outcomes of combination TIL and checkpoint inhibitor therapy for heavily pretreated patients.
• Examine the temporal dynamics of tumor response and relapse following sequential TIL treatments.

Strengths

• Document is licensed under CC-BY-4.0, permitting open sharing and adaptation.
• Provides detailed clinical timeline including specific response assessments (PR, CR, SD) at documented weeks post-infusion.
• References three specific clinical trial identifiers (NCT06697665, NCT05941936, NCT05971589) for further context.

Limitations

• Row count and column-level documentation are absent; data structure must be inferred from the narrative text.
• The dataset is a single case report (13.9 KB), representing a very limited sample size of n=1.
• Description metadata is limited; actual data quality and granularity require manual inspection after download.

Provenance

Source

figshare

Collection Method

Clinical case report and literature review.

Time Range

Temporal coverage of the case study is not explicitly stated.

Freshness

Last updated 2026-04-23 12:00:25; freshness should be verified.

Geography

Spatial coverage is not specified.